Hint mode is switched on Switch off
For swift navigation between sections

Mirum Pharmaceuticals
LEI 254900YZKR40F7F27K81

PDF download

Choose all Reset all
Download Cancel
Organization name
Mirum Pharmaceuticals, Inc.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
916 mln USD
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Unlock data Watch full tour

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).

Awards

News

19/05/2026 New issue: Mirum Pharmaceuticals issued bonds in the amount of USD 600 mln maturing in 2032
12/05/2026 Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes
12/05/2026 Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
12/05/2026 Mirum Pharmaceuticals: Entry Into A Material Definitive Agreement, Creation Of A Direct Financial Obligation Or An, Unregistered Sales Of Equity Securities, Other Events, Financial Statements And Exhibits
05/05/2026 Mirum Pharmaceuticals (NASDAQ: MIRM) Surges on Positive Volixibat Clinical Trial Results and Analyst Price Target Hike
All organization news

Documentation

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
II q eng
III q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
II q eng
III q eng
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Latest issues

Show all

Public debt by currencies

Show more Hide

Codes

  • LEI
    254900YZKR40F7F27K81
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • NACE
    *** ***
  • NAICS
    *** ***
  • CIK
    0001759425
  • EIN
    83-1281555
Registration is required to get access.